Genmab — Januar 2023
-
Det sætter medicinrådets afvisning af DRd lidt i relief. Sjældent har man set lignende: Efter 73,6 mdr er median OS not reached for DRd-armen. Det er den stærkeste kombination i historien i MM for pts som ikke er egnede til asct. Og bliver så afvist af medicinrådet. Pga prisen. Ren forhandlingstaktik fra rådets side. De er udmærket klar over at DRd er uden sidestykke i MM, men de vil have det billigere.
-
PROINVESTORS FINANSKALENDER MED DE AKTUELLE REGNSKABER
https://www.proinvestor.com/finanskalende -
-
Når man ikke rigtig bliver beriget af en 30-dages kursanalyse
-
10 top M&A targets in biotec for 2023. https://www.fiercebiotech.com/special-reports/top-10-ma-targets-biotech-2023
-
-
Godmorgen
-
Tirsdagens aviser med Tryg, Bavarian og Danish Crown https://www.proinvestor.com/investornyt/933732/tirsdagens-aviser-med-tryg-bavarian-og-danish-crown
-
Morn, Opdateret Genmab salgs / kurs estimater. Bliver opjusteret igen efter regnskab og 2023 guiding. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/109933_Skaermbillede_2023_01_31_125840_Genmab_long_term_estimate.jpg
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind